XVIPF:OTO-Xvivo Perfusion Ab Ord (USD)

COMMON STOCK | Medical Devices | OTC Pink

Last Closing

USD 26.095

Change

0.00 (0.00)%

Market Cap

USD 0.22B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Xvivo Perfusion AB is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SMMNY Siemens Healthineers AG ADR

+0.25 (+0.87%)

USD 67.12B
SEMHF Siemens Healthineers AG

N/A

USD 67.12B
RYLPF Koninklijke Philips N.V

N/A

USD 18.28B
SONVY Sonova Holding AG

+1.07 (+1.94%)

USD 16.80B
SONVF Sonova Holding AG

N/A

USD 16.20B
CHEOF Cochlear Limited

N/A

USD 13.75B
CHEOY CochLear Ltd ADR

+2.52 (+2.45%)

USD 13.71B
WILLF Demant A/S

N/A

USD 11.36B
SNNUF Smith & Nephew plc

N/A

USD 11.35B
WILYY Demant A/S ADR

N/A

USD 10.43B

ETFs Containing XVIPF

RUBY:CA RBC U.S. Banks Yield Inde.. 7.38 % 0.33 %

+0.11 (+0.00%)

CAD 0.01B
RUBY-U:CA RBC U.S. Banks Yield Inde.. 7.38 % 0.00 %

N/A

N/A
HUBL:CA Harvest US Bank Leaders I.. 6.88 % 1.57 %

N/A

CAD 0.11B
IAT iShares U.S. Regional Ban.. 4.12 % 0.42 %

-0.13 (0.00%)

USD 0.62B
BNKS:LSE iShares S&P U.S. Banks 4.00 % 0.00 %

+0.03 (+0.00%)

USD 0.34B
IUS2:F iShares S&P U.S. Banks UC.. 3.99 % 0.00 %

+0.06 (+0.00%)

USD 0.33B
IUS2:XETRA iShares S&P U.S. Banks UC.. 3.99 % 0.00 %

+0.04 (+0.00%)

USD 0.33B
UINC:LSE First Trust US Equity Inc.. 3.04 % 0.00 %

+24.50 (+0.00%)

USD 0.29B
FBU:CA 2.78 % 0.84 %

N/A

N/A
KRE SPDR® S&P Regional Banki.. 2.43 % 0.35 %

-0.28 (0.00%)

USD 2.80B
KRS 2.30 % 0.95 %

N/A

N/A
KRU 2.30 % 0.95 %

N/A

N/A
MVIN 2.28 % 0.55 %

N/A

N/A
EXX5:F iShares Dow Jones U.S. Se.. 1.59 % 0.00 %

+0.44 (+0.00%)

USD 0.35B
EXX5:XETRA iShares Dow Jones U.S. Se.. 1.59 % 0.00 %

+0.44 (+0.00%)

USD 0.37B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.45% 76% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.45% 76% C+ 73% C
Trailing 12 Months  
Capital Gain 14.96% 76% C+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.96% 76% C+ 72% C
Trailing 5 Years  
Capital Gain 81.22% 89% A- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.22% 85% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 30.39% 71% C- 71% C-
Dividend Return 30.39% 71% C- 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.40% 45% F 37% F
Risk Adjusted Return 38.27% 88% B+ 77% C+
Market Capitalization 0.22B 80% B- 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.